Predictive Oncology (POAI) Corporate Media Kit
Subsidiaries Predictive Oncology leverages the synergies of its three whol- ly-owned subsidiaries to bring the power and capabilities of precision medicine to to cancer. Helomics The company applies artificial intelligence to its rich database of 150,000 tumor cases gathered from the company’s 15+ year history of clinical testing to develop AI-driven predictive models of tumor drug response to improve the clinical outcomes for patients of today and tomorrow. This equips Helomics to collaborate with pharmaceu- tical companies and strategic partners in the development of new targeted therapies. The company’s database of drug response pro- files is enriched for ovarian, breast, lung, colon and pancreas cancers and is the largest of its kind in the world. This database continues to grow as Helomic’s CLIA-certified lab provides clinical testing and an evidence-based roadmap for therapy to assists oncologists in individualizing patient treatment decisions. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services. These leverage Helomics’ TruTumor™ patient-derived models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), as well as an AI-powered proprietary platform ”LucidAI” to build predictive models of tumor drug response that can be used to meet a variety of client needs from basic research through drug discovery to clinical trials
Made with FlippingBook
RkJQdWJsaXNoZXIy NDMyMDk=